Management of the patient with rheumatoid arthritis

  • J. -G. Tebib
  • P. Miossec


Until the early eighties, the treatment of rheumatoid arthritis (RA) was based on the principle of responding to the damage caused by disease progression at the time when the damage actually occurred. In this strategy, known as the “pyramid approach”, the physician responded to the patient’s worsening condition by initiating a possibly more effective therapeutic option, always at a late stage in disease progression. As the efficacy and toxicity of the medications available were poorly known, such a strategy generally led to inevitable deterioration of the patient’s autonomy because the decision to treat necessarily lagged behind the progress of the disease in spite of the contributions made by prosthetic surgery (1). In the eighties, three lines of research led to a complete change in planning the management of RA. Methotrexate was rediscovered as a long-acting drug and meticulous comparative studies were carried out on the efficacy and toxicity of all disease-modifying anti-rheumatic drugs (DMARD). They finally concluded on the supremacy of methotrexate both for controlling flares and for the prevention of joint destruction (2). A second line of research confirmed the importance of early diagnosis by demonstrating the rapidity of joint damage at the very onset of the disease (3) and as a corollary the need for effective, appropriate treatment started as soon as possible (4). The relative inefficacy of the basic DMARDS in arresting structural joint destruction finally led to the search for other modes of treatment. The most immediate option consisted in applying the principles of synergistic action of different treatments to fight the same entity; an approach which had yielded encouraging results against cancer or infectious diseases (5).


Rheumatoid Arthritis Joint Damage Rheumatoid Arthritis Status Rheumatoid Nodule Structural Joint Damage 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Amor B, Herson D, Cherot A, Delbarre F. Analyse du suivi de patients affectés de polyarthrite rhumatoïde sur une période supérieure à 10 ans (1966–1978): analyse de la progression et des traitements sur 10 cas. Ann Med Interne (Paris) 1981; 132(3): 168–73Google Scholar
  2. 2.
    Felson DT, Anderson JJ, Meenan RF. The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis. Results of two metaanalyses. Arthritis Rheum 1990; 33(10): 1449–61PubMedCrossRefGoogle Scholar
  3. 3.
    Fuchs HA, Kaye JJ, Callahan LF, Nance EP, Pincus T. Evidence of significant radiographic damage in rheumatoid arthritis within the first 2 years of disease. J Rheumatol 1989; 16(5): 585–91PubMedGoogle Scholar
  4. 4.
    Guidelines for the management of rheumatoid arthritis. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines. Arthritis Rheum 1996; 39(5): 713–22CrossRefGoogle Scholar
  5. 5.
    O’Dell JR. Combination DMARD therapy for rheumatoid arthritis: a step closer to the goal. Ann Rheum Dis 1996; 55(11): 781–3PubMedCrossRefGoogle Scholar
  6. 6.
    Lipsky PE, van der Heijde DM, St Clair EW et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000; 343(22): 1594–602PubMedCrossRefGoogle Scholar
  7. 7.
    Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31(3): 315–24PubMedCrossRefGoogle Scholar
  8. 8.
    Visser H, Le Cessie S, Vos K, Breedveld FC, Hazes JMW. How to diagnose rheumatoid arthritis (RA) early: the development of diagnostic criteria (abstract). Ann Rheum 2000; 59(suppl 1):35Google Scholar
  9. 9.
    American College of Rheumatology Ad Hoc Committee on Clinical Guidelines. Guidelines for the management of rheumatoid arthritis. Arthritis Rheum 1996; 39(5): 713–22CrossRefGoogle Scholar
  10. 10.
    Wakefield RJ, Gibbon WW, Conaghan PG, O’Connor P, McGonagle D, Pease C, Green MJ, Veale DJ, Isaacs JD, Emery P. The value of sonography in the detection of bone erosions in patients with rheumatoid arthritis: a comparison with conventional radiography. Arthritis Rheum 2000; 43: 2762–70PubMedCrossRefGoogle Scholar
  11. 11.
    McGonagle D, Conaghan PG, O’Connor P, Gibbon W, Green M, Wakefield R, Ridgway J, Emery P. The relationship between synovitis and bone changes in early untreated rheumatoid arthritis: a controlled magnetic resonance imaging study. Arthritis Rheum 1999;42(8): 1706–11PubMedCrossRefGoogle Scholar
  12. 12.
    van der Heijde DM, van Leeuwen MA, van Riel PL, van de Putte LB. Radiographic progression on radiographs of hands and feet during the first 3 years of rheumatoid arthritis measured according to Sharp’s method (van der Heijde modification). J Rheumatol 1995; 22(9): 1792–6PubMedGoogle Scholar
  13. 13.
    van der Heijde DM, van’t Hof M, van Riel PL, van de Putte LB. Development of a disease activity score based on judgment in clinical practice by rheumatologists. J Rheumatol 1993; 20(3): 579–81PubMedGoogle Scholar
  14. 14.
    van Zeben D, Hazes JM, Zwinderman AH, Cats A, Schreuder GM, D’Amaro J, Breedveld FC. Association of HLA-DR4 with a more progressive disease course in patients with rheumatoid arthritis. Results of a followup study. Arthritis Rheum 1991; 34(7): 822–30PubMedCrossRefGoogle Scholar
  15. 15.
    Combe B, Eliaou JF, Daures JP, Meyer O, Clot J, Sany J. Prognostic factors in rheumatoid arthritis. Comparative study of two subsets of patients according to severity of articular damage. Br J Rheumatol 1995; 34(6): 529–34PubMedCrossRefGoogle Scholar
  16. 16.
    Rau R, Herborn G, Zueger S, Fenner H. The effect of HLA-DRB1 genes, rheumatoid factor, and treatment on radiographic disease progression in rheumatoid arthritis over 6 years. J Rheumatol 2000; 27(11): 2566–75PubMedGoogle Scholar
  17. 17.
    Tugwell P, Pincus T, Yocum D, Stein M, Gluck O, Kraag G, McKendry R, Tesser J, Baker P, Wells G. Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. The Methotrexate-Cyclosporine Combination Study Group. N Engl J Med 1995; 333(3): 137–41PubMedCrossRefGoogle Scholar
  18. 18.
    Mottonen T, Hannonen P, Leirisalo-Repo M, Nissila M, Kautiainen H, Korpela M, Laasonen L, Julkunen H, Luukkainen R, Vuori K, Paimela L, Blafield H, Hakala M, Ilva K, Yli-Kerttula U, Puolakka K, Jarvinen P, Hakola M, Piirainen H, Ahonen J, Palvimaki I, Forsberg S, Koota K, Friman C. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group. Lancet 1999; 353(9164): 1568–73PubMedCrossRefGoogle Scholar
  19. 19.
    Weinblatt ME, Kremer JM, Coblyn JS, Maier AL, Helfgott SM, Morrell M, Byrne VM, Kaymakcian MV, Strand V. Pharmacokinetics, safety, and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis. Arthritis Rheum 1999; 42(7): 1322–8PubMedCrossRefGoogle Scholar
  20. 20.
    Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, Smolen JS, Weisman M, Emery P, Feldmann M, Harriman GR, Maini RN; Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000; 30; 343(22): 1640–1CrossRefGoogle Scholar
  21. 21.
    Kirwan JR. The effect of glucocorticoids on joint destruction in rheumatoid arthritis. The Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group. N Engl J Med 1995; 333(3): 142–6PubMedCrossRefGoogle Scholar
  22. 22.
    Bouysset M, Tebib J, Noel E, Eulry F, Bonnin M, Nemoz C, Bouvier M. When should orthopaedic treatment be prescribed to avoid the flattening of the rheumatoid foot? Clin Rheumatol 1992; 11(4): 580–2PubMedCrossRefGoogle Scholar
  23. 23.
    Pincus T, O’Dell JR, Kremer JM. Combination therapy with multiple disease-modifying antirheumatic drugs in rheumatoid arthritis: a preventive strategy. Ann Intern Med 1999; 131(10): 768–74PubMedGoogle Scholar

Copyright information

© Springer Verlag France 2006

Authors and Affiliations

  • J. -G. Tebib
    • 1
  • P. Miossec
    • 2
  1. 1.Centre hospitalier Lyon-SudPierre-BéniteFrance
  2. 2.Service de rhumatologie et de pathologie osseuseHôpital Edouard-Herriot, pavillon FLyon Cedex 03France

Personalised recommendations